Elekta AB (publ)
STO:EKTA B

Watchlist Manager
Elekta AB (publ) Logo
Elekta AB (publ)
STO:EKTA B
Watchlist
Price: 60.45 SEK 0.25% Market Closed
Market Cap: 23.1B SEK
Have any thoughts about
Elekta AB (publ)?
Write Note

Elekta AB (publ)
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Elekta AB (publ)
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Elekta AB (publ)
STO:EKTA B
Cash from Investing Activities
-kr1.9B
CAGR 3-Years
-46%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Cash from Investing Activities
-kr47.2m
CAGR 3-Years
74%
CAGR 5-Years
26%
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Cash from Investing Activities
-kr74.5m
CAGR 3-Years
1%
CAGR 5-Years
-30%
CAGR 10-Years
-17%
Getinge AB
STO:GETI B
Cash from Investing Activities
-kr6.5B
CAGR 3-Years
-49%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Cash from Investing Activities
-kr637m
CAGR 3-Years
13%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Sedana Medical AB (publ)
STO:SEDANA
Cash from Investing Activities
-kr31.4m
CAGR 3-Years
34%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Elekta AB (publ)
Glance View

Market Cap
23.1B SEK
Industry
Health Care

Elekta AB emanates sophistication and precision, standing at the forefront of medical technology. Established in 1972 by Lars Leksell, the Swedish innovator manifests a legacy deeply rooted in advancing oncology and neurosurgery treatment solutions. Elekta's forte lies in crafting state-of-the-art equipment and software that assist medical practitioners in treating complex cancers and brain disorders. Their products, such as the Leksell Gamma Knife and various advanced linear accelerators, showcase their commitment to minimally invasive treatment. By developing cutting-edge systems that refine radiation therapy and radio-surgery, Elekta plays a pivotal role in enhancing patient outcomes, offering more precise targeting of tumors with minimal damage to surrounding healthy tissues. Financially, Elekta thrives through a multi-faceted revenue model that harmoniously blends hardware sales with recurring income from maintenance services, software upgrades, and training. Their business strategy capitalizes on long-term relationships with healthcare providers, ensuring a steady demand for both product innovation and servicing their existing installations. By anchoring its revenue stream in this hybrid fashion, Elekta offers a compelling proposition for shareholders—a blend of resilient cash flow dynamics and growth through groundbreaking technological advancements. As the global healthcare landscape evolves, Elekta's continuous investment in research and development ensures they remain a venerated leader in tackling the world's challenges in cancer care and neurological disorders.

EKTA B Intrinsic Value
96.75 SEK
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Elekta AB (publ)'s Cash from Investing Activities?
Cash from Investing Activities
-1.9B SEK

Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Cash from Investing Activities amounts to -1.9B SEK.

What is Elekta AB (publ)'s Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-23%

Over the last year, the Cash from Investing Activities growth was -19%. The average annual Cash from Investing Activities growth rates for Elekta AB (publ) have been -46% over the past three years , -23% over the past five years .

Back to Top